8/12/2008

• Geron and Exeter Life Sciences Merge Start Licensing and Viagen To Form Combined Licensing and Operating Company for Animal Cloning Technologies

8/7/2008

• Geron Initiates Clinical Trial of GRN163L in Combination with Paclitaxel and Bevacizumab in Patients with Breast Cancer

7/30/2008

• Geron Corporation Reports 2008 Second Quarter Financial Results and Events

6/12/2008

• Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell Therapeutic for Heart Failure Evades Direct Attack by the Human Immune System

6/10/2008

• Geron Corporation to Present at Needham & Company Biotechnology and Medical Technology Conference

6/2/2008

• Geron Presentations at the ASCO 2008 Annual Meeting

5/14/2008

• Stemcell Technologies, Inc. Licenses Geron Intellectual Property For The Development Of Media And Matrices For Stem Cell Growth

5/14/2008

• FDA Places Geron’s GRNOPC1 IND on Clinical Hold

5/12/2008

• Geron Corporation to Present at Bank of America Health Care Conference

5/6/2008

• University of Edinburgh Human Embryonic Stem Cell Program Awarded UK Grant Funding

4/29/2008

• Geron Reports 2008 First Quarter Financial Results

4/16/2008

• Geron Presentations at the AACR 2008 Annual Meeting

4/15/2008

• Geron Receives Milestone Payment From Exeter Life Sciences

3/11/2008

• U.S. Patent Office Upholds Two Additional Human Embryonic Stem Cell Patents in Reexamination Decisions

2/28/2008

• U.S. Patent Office Upholds Key Human Embryonic Stem Cell Patent

2/27/2008

• Geron Corporation Reports Fourth Quarter and Annual 2007 Financial Results and Highlights

2/14/2008

• Geron Ranked in Biotechnology Patent Scorecard Published in The Wall Street Journal

2/8/2008

• Geron Corporation to Present at BIO CEO & Investor Conference

2/5/2008

• Geron´s Second U.S. Patent for Production of Pancreatic Islets From Human Embryonic Stem Cells Strengthens Company´s Intellectual Property Position

1/25/2008

• Dr. Thomas Okarma Resumes Direct Leadership of Geron´s Oncology Drug Development Activities

1/24/2008

• Geron and Sienna Enter Into License Agreement for Cancer Diagnostics

12/12/2007

• Geron Receives Milestone Payment From Merck Triggered by IND Filing for Telomerase Cancer Vaccine Candidate

11/28/2007

• Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Patients with Multiple Myeloma

11/27/2007

• Geron Corporation to Present at Lazard Capital Markets Healthcare Conference

11/21/2007

• Recent Advances in Cellular Reprogramming

11/13/2007

• Journal of Neuroimmunology Publishes Study Results Showing that Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

11/7/2007

• Data Show Geron´s Cell-Based Therapeutic for Spinal Cord Injury Survives and Exhibits Remyelination for at Least Nine Months Following Injection

11/2/2007

• Geron Corporation to Present at Rodman & Renshaw Healthcare Conference

10/30/2007

• Geron Corporation Reports 2007 Third Quarter Financial Results and Events

10/9/2007

• Geron Corporation to Present at Biotechnology Industry Organization Investor Forum

9/24/2007

• Geron Corporation to Present at UBS Global Life Sciences Conference

9/4/2007

• Pharmexa Loses European Patent Appeal for Broad Claims to Telomerase-Based Cancer Vaccines

8/27/2007

• Geron Scientists and Collaborators Demonstrate Human Embryonic Stem Cell-Derived Cardiomyocytes Improve Heart Function When Transplanted After Myocardial Infarction

7/30/2007

• Geron Corporation Reports 2007 Second Quarter Financial Results and Events

7/11/2007

• Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia

7/9/2007

• Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Combination with Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer

7/5/2007

• Geron Corporation to Host Analyst and Investor Meeting in New York City on July 17, 2007

6/19/2007

• Research Documents Scalable Production, Survival Following Engraftment and Positive Impact On Cardiac Function in Infarcted Rats for Geron’s Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

6/18/2007

• Geron Increases Stake in TA Therapeutics Joint Venture

6/12/2007

• Geron Corporation to Present at Needham & Company Biotechnology and Medical Technology Conference

6/12/2007

• Geron´s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

6/11/2007

• Research Indicates Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

5/31/2007

• Geron Corporation to Present at Banc of America Health Care Conference

5/17/2007

• Geron Scientists and Collaborators Differentiate Human Embryonic Stem Cells Into Insulin-Producing Islet-Like Clusters

5/11/2007

• Geron Corporation to Present at Rodman & Renshaw Healthcare Conference

5/7/2007

• Geron Corporation to Present at UBS Global Generic & Specialty Pharmaceuticals Conference

4/27/2007

• Geron Corporation Reports 2007 First Quarter Financial Results

4/25/2007

• Telomerase Presentations at the AACR 2007 Annual Meeting

4/24/2007

• Geron and CXR Conclude Collaboration to Develop In Vitro Assays Using hESC-Derived Hepatocytes

4/19/2007

• Studies Confirm Proof-of-Principle for Geron´s Human Embryonic Stem Cell (hESC) Derived Hepatocytes

4/2/2007

• Geron Supports WARF´s Claims to Human Embryonic Stem Cell Patents

3/16/2007

• Geron Corporation Reports Fourth Quarter and Annual 2006 Financial Results and Highlights

3/12/2007

• Geron Grants License to Asia Biotech Corporation

3/9/2007

• Geron to Restate Financial Results of Prior Periods

2/27/2007

• Geron Corporation Announces Exercise Of Warrants for $15.0 Million of Proceeds

2/15/2007

• Unique Structure of Geron´s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells

2/9/2007

• Geron Corporation to Present at BIO CEO & Investor Conference

1/17/2007

• Studies Show Geron´s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors

12/19/2006

• Geron´s Telomerase Inhibitor Drug May Benefit Breast Cancer Patients Receiving Radiation Therapy

12/14/2006

• Geron Announces Direct Equity Issuance

12/11/2006

• Data Show Geron´s Telomerase Inhibitor Cancer Drug Is Active Against Cancer Stem Cells From Multiple Myeloma Patients

11/28/2006

• Geron Corporation to Present at Lazard Life Sciences Conference

11/10/2006

• Geron Presents Early Clinical Trial Data for Its Telomerase Inhibitor Cancer Drug

11/7/2006

• Geron to Present at Rodman & Renshaw 8th Annual Healthcare Conference

11/6/2006

• Geron Licenses Antigen Targeting Patents for Cancer Vaccine Program from Immunomic Therapeutics

10/30/2006

• Geron Corporation Reports 2006 Third Quarter Financial Results and Events

10/27/2006

• Geron Announces Conference Call to Discuss Financial Results for the 2006 Third Quarter

10/16/2006

• Geron Appoints Alan Colowick as President, Oncology

9/6/2006

• Geron Announces Dismissal of Patent Interference Appeals

8/21/2006

• Geron Presents Data on HIV/AIDS Drug Candidate at the XVI International AIDS Conference

8/7/2006

• Geron, University of Edinburgh Form Collaboration for Development of Three Cell Types Derived From Human Embryonic Stem Cells

7/31/2006

• Geron Corporation Reports 2006 Second Quarter Financial Results and Events

7/28/2006

• Geron Announces Conference Call to Discuss Financial Results for the 2006 Second Quarter

7/19/2006

• Geron Announces Publication of Study Results Supporting Safety and Utility of Human Embryonic Stem Cell-Derived Therapeutic Product for Treatment of Spinal Cord Injury

7/18/2006

• Geron to Host Analyst Day

7/13/2006

• Geron Announces Publication of Improved Methods for Manufacturing of Its Anti-Cancer Drug, GRN163L

7/5/2006

• Geron Presents New Data That Document Progress in Development of Therapeutic Products From Human Embryonic Stem Cells

6/29/2006

• Invitrogen Licenses Geron Intellectual Property for Development of Research Tools

6/22/2006

• Geron Announces Collaboration to Develop Synthetic Surfaces for Growth of Embryonic Stem Cells

6/15/2006

• Geron Announces Ruling From European Patent Office

6/13/2006

• Geron Corporation to Present at Needham & Company Biotechnology and Medical Technology Conference

5/23/2006

• Geron Announces Publication of First In Vivo Data Demonstrating Efficacy of GRN163L in Models of Primary and Metastatic Breast Cancer

5/18/2006

• Geron Names Laurence Elias, M.D., Vice President, Oncology Clinical Development

5/16/2006

• Geron Corporation To Present at the Bank of America Healthcare Conference

5/15/2006

• Geron and TA Therapeutics Announce Presentation of New Data Supporting Utility of Their Small Molecule Telomerase Activator TAT0002

4/28/2006

• Geron Corporation Reports 2006 First Quarter Financial Results

4/27/2006

• Geron Announces Conference Call to Discuss Financial Results for the 2006 First Quarter

4/26/2006

• Geron Announces Issuance of U.S. Patent for Production of Insulin Secreting Cells from Human Embryonic Stem Cells

4/21/2006

• Geron Corporation to Present at UBS Global Specialty Pharmaceuticals Conference

4/6/2006

• Geron Corporation Announces Multiple Presentations on Telomerase at the AACR 2006 Annual Meeting

4/3/2006

• Geron Announces Initiation of Clinical Trial for Its Telomerase Inhibitor Drug GRN163L in Patients with Solid Tumor Malignancies

3/27/2006

• Geron Enters into Research and Exclusive License Agreements with the University of Oxford for Derivation of Dendritic Cells from Human Embryonic Stem Cells

3/3/2006

• Geron Corporation To Present At Cowen & Co. Health Care Conference

2/28/2006

• Geron Corporation Reports Fourth Quarter And Annual 2005 Financial Results And Events

2/27/2006

• Geron Announces Conference Call To Discuss Financial Results For The Year End

2/26/2006

• 60 Minutes will be airing a segment on human embryonic stem cells on Sunday, February 26, 2006 at 7:00pm ET/PT. Click here for more information.

2/22/2006

• Geron Announces Studies Demonstrating That Cardiomyocytes Derived From Human Embryonic Stem Cells Engraft And Prevent Heart Failure In The Infarcted Rodent Heart

2/15/2006

• Geron Licenses Maxcyte Cell Loading Technology For Use In Closed-System Cancer Vaccine Manufacturing

2/13/2006

• Geron And Cambrex Announce Contract Manufacturing Arrangement For cGMP Production Of GRNVAC1 For Clinical Trials

2/10/2006

• Geron Corporation To Present At BIO CEO Conference

2/7/2006

• Geron Announces Commercial Launch Of Telomerase-Immortalized Cell Line

2/3/2006

• Geron Announces Presentation Of New Data Supporting The Utility Of Its Small Molecule Telomerase Activator Drugs For HIV/AIDS Therapy

2/2/2006

• Geron Clarifies License Rights For Cancer Vaccines

1/27/2006

• Geron Announces Improved Production Method For Human Embryonic Stem Cell-Derived Islet Cells

12/12/2005

• Geron Announces Data On The Effects Of Its Cancer Drug, GRN163L, On Multiple Myeloma At The American Society Of Hematology Annual Meeting

11/28/2005

• Geron To Present At Lazard Capital Markets Life Sciences Conference

11/4/2005

• Geron Corporation Reports 2005 Third Quarter Financial Results And Events

9/23/2005

• Geron To Present At UBS Global Life Sciences Conference

9/22/2005

• Geron Corporation Announces Closing Of Its Common Stock Offering

9/20/2005

• Geron Corporation Announces Exercise Of Over-Allotment Option

9/16/2005

• Geron Corporation Announces The Pricing Of Its Common Stock Offering

9/12/2005

• Geron Corporation Announces Common Stock Offering

9/6/2005

• Geron Announces Publications Demonstrating Efficacy Of GRN163L, Its Pan-Cancer Drug, In Animal Models Of Human Liver And Lung Cancer

9/1/2005

• Geron Announces Publication Of Studies Demonstrating Engraftment Of Human Embryonic Stem Cell-Derived Cardiomyocytes In The Rodent Heart

8/5/2005

• Geron Corporation Reports 2005 Second Quarter Financial Results And Events

7/27/2005

• Geron Announces Initiation Of Clinical Trial For Its Telomerase Inhibitor Drug GRN163L In Patients With Chronic Lymphocytic Leukemia

7/19/2005

• Geron Corporation Appoints Charles Homcy To Its Board Of Directors

7/18/2005

• Geron Enters Into A Collaboration And License Agreement With Merck & Co., Inc. For Cancer Vaccines Targeting Telomerase

6/23/2005

• Geron Provides Update On Human Embryonic Stem Cell Programs At International Society For Stem Cell Research Annual Meeting

6/22/2005

• Geron Announces Publication Describing Hematopoietic Cells Derived From Human Embryonic Stem Cells (hESCs)

6/21/2005

• Geron Publication Describes Human Embryonic Stem Cells Propagated Using Defined Serum-Free Medium In The Absence Of Animal-Derived Products Or Feeder Cells

6/1/2005

• Geron Announces Publication Characterizing GRN163L, Its Telomerase Inhibitor Drug Currently In Clinical Development For Cancer

5/25/2005

• Geron Corporation To Present At Needham & Company Fourth Annual Biotechnology Conference

5/23/2005

• Geron Announces FDA Clearance To Start Clinical Trials Of Its Telomerase Inhibitor Drug GRN163L In Patients With Chronic Lymphocytic Leukemia

5/20/2005

• Geron Corporation To Present At UBS 2005 Global Pharmaceuticals Conference

5/12/2005

• Geron Announces Publication Describing Animal Cell-Free Derivation Of Human Embryonic Stem Cells

5/11/2005

• Geron Announces Publication Of Studies Showing Oligodendrocyte Progenitors Derived From Human Embryonic Stem Cells Induce Functional Recovery After Spinal Cord Injury

5/10/2005

• Geron Announces Publication Of Studies Demonstrating Hematopoietic Stem Cells Differentiated From Human Embryonic Stem Cells Engraft And Establish Hematopoiesis In Animals

4/29/2005

• Geron Corporation Reports 2005 First Quarter Financial Results And Events

4/25/2005

• Geron Announces Equity Issuance To Hong Kong Investors

4/20/2005

• Geron Corporation Announces Multiple Presentations On Its Telomerase Inhibitor Drug GRN163L At The AACR 2005 Annual Meeting

4/6/2005

• Geron And Exeter Life Sciences Form Joint Venture For Licensing Animal Cloning Technologies

3/8/2005

• Geron Announces Publication Of Studies Demonstrating That Human Embryonic Stem Cells Can Be Grown With Defined Growth Factors Enabling Scaled Production Of Therapeutic Cells

3/7/2005

• Geron Announces Presentation Of Data Supporting The Utility Of Small Molecule Telomerase Activators For HIV/AIDS Therapy

3/4/2005

• Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer

3/1/2005

• Geron And Hong Kong´s Biotechnology Research Corporation Form Strategic Alliance For Telomerase Activation Therapies

2/25/2005

• Geron Corporation Reports Fourth Quarter And Annual 2004 Financial Results And Highlights

2/24/2005

• Geron Wins Favorable Final Judgment In Third Nuclear Transfer Patent Interference

2/18/2005

• Geron Corporation To Present At BIO CEO Conference

1/11/2005

• Geron Announces License Agreement With Cambrex For Distribution Of Telomerase-Immortalized Human Cell Lines

1/6/2005

• U.S. Patent Office Enters Final Judgment In Nuclear Transfer Patent Interference In Favor Of Geron

12/21/2004

• Geron Corporation Receives U.S. Patent For Differentiating Human Embryonic Stem Cells Into Neural Cells

11/24/2004

• Geron Corporation To Present At Lazard´s Life Sciences Conference

11/22/2004

• Geron Announces Publication Of Study Results Showing That Human Embryonic Stem Cell-Derived Oligodendrocytes Remyelinate In Vivo

11/18/2004

• Geron Presents Data On Human Embryonic Stem Cell-Based Therapy For Heart Failure

11/18/2004

• Geron Presents Data On Human Embryonic Stem Cell-Based Therapy For Diabetes

11/16/2004

• Geron Licenses Nuclear Transfer Technology To Revivicor, Inc.

11/15/2004

• Geron Corporation To Present At SG Cowen’s 5th Annual Global Health Care Conference

11/15/2004

• Geron Announces Publication Of Additional Data Supporting The Utility Of Telomerase Activation For HIV/AIDS Therapy

11/11/2004

• Geron Announces Direct Equity Issuance

11/11/2004

• Geron Announces Publication Of Studies Showing That Cells Derived From Human Embryonic Stem Cells Can Be Immortalized By Telomerase

11/8/2004

• Geron Announces Presentations On GRN163L And Its Telomerase Vaccine At The AACR Special Conference On The Role Of Telomerase In Cancer

10/29/2004

• Geron Corporation Reports 2004 Third Quarter Results And Events

10/22/2004

• Geron Corporation To Present At Rodman & Renshaw Techvest Conference

10/11/2004

• Geron Corporation To Present At BIO Emerging Company Investor Forum

10/5/2004

• Geron Corporation Receives U.S. Patent For Feeder-Free Growth Of Human Embryonic Stem Cells

9/23/2004

• Geron Corporation To Present At UBS Global Life Sciences Conference

8/12/2004

• Geron Announces Publication Showing In Vivo Efficacy Of An Oncolytic Virus Containing The Telomerase Promoter

7/30/2004

• Geron Corporation Reports 2004 Second Quarter Results

7/27/2004

• Geron Announces Publication Showing Human Embryonic Stem Cells Possess Unique Immune Properties

7/7/2004

• Geron Announces Telomerase License Agreement With Procter & Gamble

7/1/2004

• Geron Announces Publication Of Data On GRN163, A Telomerase Inhibitor, In Animal Models Of Human Brain Tumors

6/30/2004

• Geron And Kyowa Hakko Announce Agreement To Conclude Collaboration

6/22/2004

• Kirin And Geron Announce Settlement Of Lawsuit

6/15/2004

• Geron Corporation To Present At Needham & Company Third Annual Biotechnology Conference

6/14/2004

• Geron Announces Presentations Showing Progress In Development Of Human Embryonic Stem Cell-Based Therapies

6/7/2004

• Geron Reports Presentation of Positive Results of Telomerase Cancer Vaccine Clinical Trial

5/20/2004

• Geron, CXR Biosciences and the Roslin Institute Announce Partnership to Develop In Vitro Assays Using hESC-Derived Hepatocytes

5/18/2004

• Geron Corporation To Present At Banc Of America Securities Health Care Conference

5/17/2004

• Geron Corporation Announces Publication Of Genetic Data Describing Genes Linked To The Growth And Differentiation of Human Embryonic Stem Cells

5/12/2004

• Geron Announces Presentation Of Results Of Telomerase Cancer Vaccine Clinical Trial At Duke

5/11/2004

• Geron Corporation To Present At Rodman & Renshaw Techvest Global Healthcare Conference

5/10/2004

• Geron And ATCC Announce Telomerase Licensing Agreement

4/29/2004

• Geron Corporation Reports 2004 First Quarter Financial Results And Events

4/28/2004

• Geron Announces Notice Of Lawsuit

4/27/2004

• Geron Grants License for Nuclear Transfer Technology to XenoTrans

3/30/2004

• Geron Announces New Data On GRN163L, A Telomerase Inhibitor Drug For Cancer Therapy

3/29/2004

• Geron And Xcellsyz Ltd. Announce Telomerase Licensing Agreement

3/18/2004

• Geron Receives Favorable Ruling In Nuclear Transfer Patent Interference: Opponent´s Patent Claims Are Found Unpatentable, Geron’s Patent Claims Are Upheld

3/10/2004

• Geron Corporation And Merix Bioscience, Inc. Announce a Co-Exclusive License Agreement For Therapeutic Cancer Vaccines

2/27/2004

• Geron Corporation Reports Fourth Quarter And Annual 2003 Financial Results And Highlights

2/20/2004

• Geron Corporation To Present At BIO CEO Conference

1/27/2004

• Patent Office Enters Final Judgment In Patent Interference In Favor Of Geron

1/15/2004

• Geron Receives Favorable Ruling In Nuclear Transfer Patent Interference

1/12/2004

• Geron Corporation Announces Receipt Of $12.5 Million Of Proceeds From Exercise Of Warrants

12/15/2003

• Geron Reports Publication Of Studies Demonstrating Long-Term Stability And Biological Uniformity Of Different Human Embryonic Stem Cell Lines

12/9/2003

• Geron Announces New Data On The Effects Of Its Telomerase Inhibitor Drugs On Multiple Myeloma

12/8/2003

• Geron Reports Presentation Of Further Results Of Telomerase Cancer Vaccine Clinical Trial At Duke University Medical Center

11/20/2003

• Geron Reports Positive Data On GRN163L, A Lipidated Telomerase Inhibitor Drug For The Treatment Of Cancer

11/19/2003

• Geron Announces Development Of Defined Culture Medium For The Propagation Of Human Embryonic Stem Cells

11/13/2003

• Geron Announces Presentation Of Pre-Clinical Studies On Human Embryonic Stem Cell-Based Treatment Of Acute Spinal Cord Injury

11/12/2003

• Geron Corporation Reports 2003 Third Quarter Results And Events

11/7/2003

• Geron Corporation Receives U.S. Patent For Stem Cell Culture Medium

11/5/2003

• Geron Corporation Announces Exercise Of Over-Allotment Option

10/29/2003

• Geron Corporation Announces Pricing Of Public Offering Of Five Million Shares For Gross Proceeds Of $60 Million

10/15/2003

• Geron Corporation Announces Common Stock Offering Of Five Million Shares

10/3/2003

• Geron Receives U.S. Patent For Pluripotent Stem Cells Modified For Therapeutic Applications

9/18/2003

• Geron Corporation To Present At UBS Warburg Global Life Sciences Conference

8/26/2003

• Geron Receives U.S. Patent For Human Telomerase Promoter Triggering Milestone Payment

8/20/2003

• Geron Reports On Successful Engraftment Of Cardiomyocytes Derived From Human Embryonic Stem Cells

8/19/2003

• Geron Receives U.S. Patent For Its Leading Telomerase Inhibitor Drugs

7/30/2003

• Geron Corporation Reports 2003 Second Quarter Results And Events

7/15/2003

• Geron Announces Publication Of Data On Systemic Administration And Mechanism Of Action Of Its Telomerase Inhibitor Anti-Cancer Drug

7/14/2003

• Geron Reports On Preclinical Safety Studies Of GRN163, An Inhibitor Of Telomerase For The Treatment Of Cancer

7/10/2003

• Geron Corporation Announces Successful Derivation Of Osteoblasts From Human Embryonic Stem Cells

7/1/2003

• Geron Announces Completion Of Celera Genomics Collaboration And Characterization Of Active Genes In Human Embryonic Stem Cells

6/11/2003

• Geron Announces UK Authorization For Stem Cell Derivation

6/4/2003

• Transgenomic Inc. And Geron Corporation Sign Licensing Agreement Covering Novel Class Of Synthetic Nucleic Acids

6/3/2003

• Geron Corporation To Present At Needham & Company Second Annual Biotechnology Conference

5/27/2003

• Geron Amends Debentures

5/22/2003

• Geron Corporation Announces Publication On The Production Of Hematopoietic Cells From Human Embryonic Stem Cells

4/30/2003

• Geron Corporation Reports 2003 First Quarter Financial Results And Events

4/16/2003

• Geron Corporation Announces Issuance Of U.S. Patent For Pig Cloning

4/15/2003

• Geron Receives U.S. Patent Covering Use Of Telomerase Inhibitors In Patients

4/8/2003

• Geron Announces Direct Equity Issuance

4/7/2003

• Geron To Present Preliminary Results Of Telomerase Cancer Vaccine Clinical Trial At Duke

4/3/2003

• Geron Reports Advances In Its Human Embryonic Stem Cell Programs

4/1/2003

• Geron Demonstrates Differentiation Of Hepatocytes From Human Embryonic Stem Cells

3/18/2003

• Geron Corporation Reports Publication Of Research Supporting The Utility Of Telomerase As A Universal Antigen For Cancer Immunotherapy

3/6/2003

• Geron Announces Telomerase Licensing Agreement With PanCel Corporation

3/5/2003

• Australian Patent Office Grants Geron’s Nuclear Transfer Patents Following Withdrawal Of Oppositions

2/28/2003

• Geron Corporation Reports Fourth Quarter And Annual 2002 Financial Results

2/24/2003

• Geron Corporation To Present At BIO CEO Conference

2/18/2003

• Geron Announces Publication Indicating A Role For Telomerase Activation In AIDS Therapy

1/21/2003

• Geron Prioritizes R&D Resources

1/21/2003

• Geron Corporation Announces New Data On The Production Of Hematopoietic Cells From Human Embryonic Stem Cells

1/14/2003

• Geron Corporation Obtains U.S. Patent For Drug Screening Using Human Embryonic Stem Cell-Derived Hepatocytes

1/9/2003

• Geron Corporation Reports Publication Supporting The Utility Of Telomerase Inhibition For Cancer